FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity?

D. P. Modest*, U. P. Neumann, J. Pratschke

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

1 Citation (Web of Science)
Original languageEnglish
Pages (from-to)71-73
Number of pages3
JournalEuropean Journal of Cancer
Volume73
DOIs
Publication statusPublished - Mar 2017

Keywords

  • EARLY TUMOR SHRINKAGE
  • RESECTION
  • CHEMOTHERAPY
  • CETUXIMAB
  • SURVIVAL
  • DISEASE
  • TRIAL

Cite this